Cipla Europe NV, a global pharmaceutical company has signed a distribution agreement with Serum Institute of India Ltd to market the paediatric vaccines in Europe. Cipla will seek European Medicines Agency approval and market the products in Europe.
With this tie-up Cipla has entered in to vaccines segment. The vaccines will be manufactured in Serum's production facilities approved by WHO.
Commenting on the collaboration, Mr Subhanu Saxena, MD and Global CEO, Cipla said: "We are proud to have entered into a strategic Europe-specific partnership with Serum Institute of India. This collaboration is aligned with our commitment to access to affordable paediatric healthcare. Both Cipla and SII share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contribute in eradication of childhood diseases."
Mr Adar Poonawalla, CEO and executive director, SII said, "Serum Institute believes that this tie-up with Cipla is a perfect platform for making vaccines available for Europeans as Serum also shares the common philosophy of Cipla of making vaccines/pharmaceutical products available at the most affordable prices. Therefore as the two companies are aligned in many ways, we feel this will be a good partnership."
Over the last 6 months, Cipla has strengthened its foundation in Europe. The company has launched respiratory products such as Salmeterol/Fluticasone in Germany and Sweden, Czech Republic, Slovakia and Croatia. In July, Cipla has signed an exclusive partnership with BioQuiddity to market OneDoseReadyfusORTM in regional anesthetic applications for post-surgical pain management.
